<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843388</url>
  </required_header>
  <id_info>
    <org_study_id>2306</org_study_id>
    <secondary_id>Eudra CT: 2008-004839-38</secondary_id>
    <nct_id>NCT00843388</nct_id>
  </id_info>
  <brief_title>A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria</brief_title>
  <official_title>A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind, randomized, cross over study in type 1 diabetic patients. 20 patients, age
      18-65 years is treated with spironolacton (Hexalacton (R)) for 60 days followed by 60 days
      treatment with placebo(or opposite). Primary aim: albuminuria, an expected decrease during
      hexalacton treatment. Secondary aim: ambulatory blood pressure, GFR, plasma-renin,
      angiotensin, aldosteron.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>albuminuria, expected decrease</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ambulatory blood pressure</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma renin, angiotensin, aldosteron</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Nephropathy</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 days treatment with tablet hexalacton 25 mg OD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive drug of 25 mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolacton (hexalacton(R))</intervention_name>
    <description>Tablet Spironolacton 25 mg OD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablet</intervention_name>
    <description>placebo tablet 25 mg OD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes

          -  age 18-80 years

          -  microalbuminuria

        Exclusion Criteria:

          -  blood pressure&gt; 160/100 mmHg

          -  persistent macroalbuminuria

          -  pregnancy or in risc of this

          -  P-Potassium&gt;5.7 mmol/l

          -  Eplerone treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stine e nielsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter Rossing</name_title>
    <organization>Steno Diabetes Center, Dep 520</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 2, 2012</submitted>
    <returned>October 2, 2012</returned>
    <submitted>October 31, 2012</submitted>
    <returned>November 27, 2012</returned>
    <submitted>December 19, 2012</submitted>
    <returned>January 29, 2013</returned>
    <submitted>July 5, 2013</submitted>
    <returned>August 6, 2013</returned>
    <submitted>January 30, 2015</submitted>
    <returned>February 18, 2015</returned>
    <submitted>July 7, 2015</submitted>
    <returned>July 15, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

